November 27, 2023
(press release)
–
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under Title III of the Defense Production Act, the White House announced Nov. 27 as it convened the first meeting of the White House Council on Supply Chain Resilience. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.